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FMS-like tyrosine kinase 3 (FLT3) internal tandem duplication (ITD) is a somatic mutation associated with poor
outcome when treated with chemotherapy alone. In children, hematopoietic stem cell transplantation (HSCT) is
recommended, but very limited data on outcome are reported. We determined the outcome of 29 childrenwith
FLT3/ITDepositive acute myelogenous leukemia (AML) who underwent allogeneic HSCT in 4 pediatric centers.
Eleven patients (38%) received matched related donor hematopoietic stem cells and 18 (62%) received alter-
native donors. Eighteen patients (62%) received total body irradiation (TBI)ebased regimens. No patients
experienced transplantation-related mortality. Eleven patients (38%) experienced relapsed disease. The cu-
mulative incidence of relapse at 2 years was 34.7% (95% conﬁdence interval [CI], 20.4% to 54.9%). Two-year
disease-free survival (DFS) and overall survival (OS) were 65.3% (95% CI, 45.1% to 79.6%) and 82.2% (95% CI,
58.5% to 91.3%), respectively. There was no difference in the DFS of patients who received transplants from
related donors versus the DFS of those who received transplants from alternative donors (hazard ratio [HR],
2.64; 95% CI, .79 to 8.76; P ¼ .10), using univariate analysis. Patients with higher FLT3/ITD ratio at diagnosis had
signiﬁcantly worse DFS (HR, 1.42; 95% CI, 1.04 to 1.93; P ¼ .03). The use of TBI in the preparative regimen was
associated with superior DFS (HR, .29; 95% CI, .08 to .99; P ¼ .04) and OS (HR, .07; 95% CI, .01 to .62; P ¼ .002).
We conclude that allogeneic HSCT improves DFS and OS in children with FLT3/ITDepositive AML compared
with what has been reported in those treated with chemotherapy alone.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Acute myeloid leukemia (AML) in children is a heteroge-
neous disease and a small subset of patients undergo alloge-
neic hematopoietic stem cell transplantation (HSCT) while in
ﬁrst complete remission (CR1) [1]. Generally patients with
high-risk features will proceed to transplantation when a
suitable donor is identiﬁed. FMS-like tyrosine kinase 3/inter-
nal tandem duplication (FLT3/ITD) is a molecular mutation,edgments on page 175.
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14.08.008present in 13% to 35% of AML patients [2,3]. The presence of
FLT3/ITD is increasingly being recognized as carrying a poor
prognosis when treated with chemotherapy alone [4,5]. The
FLT3/ITD allelic ratio itself also has an impact on relapse rate:
patients who have a high allelic ratio experience a higher rate
of relapse than thosewith a lower allelic ratio [6,7]. The role of
allogeneic HSCT in improving the poor outcome observed
with chemotherapy alone in adult patients with FLT3/ITDAML
is mixed [4,8-10]. In a large study of 1135 adults with AML,
therewas no evidence to support the use of allogeneic HSCT in
CR1 [8]. Other studies have shown some beneﬁt for the use of
allogeneic HSCT in adults with FLT3/ITD, although those
patients seem to have worse disease-free survival (DFS),
compared with patients with no FLT3/ITD, after allogeneic
HSCT [4,9,10]. In children, allogeneic HSCT in CR1 is recom-
mended when high-risk features are present, including
Table 1
Patient and Transplantation Characteristics
Characteristic Value
No. of patients 29
Age, median (range), yr 10.2 (4.5-21.9)
Gender, male/female 16/13
Remission status
CR1 26 (90%)
CR2 1 (3%)
Refractory 2 (7%)
Preparative regimen
TBI/Cy  ﬂudarabine 18 (62%)
BU/CY  other 11 (38%)
Donors
HLA identical 11 (38%)
Mismatched related 2 (7%)
Matched unrelated 7 (24%)
Cord blood 9 (31%)
Stem cell Source
Bone marrow 16 (55%)
Peripheral blood stem cells 4 (14%)
Cord blood 9 (31%)
GVHD prophylaxis
CSP or FK/MTX 19 (66%)
CSP/MMF 9 (31%)
None 1 (3%)
Cy indicates cyclophosphamide; Bu, busulfan; CSP, cyclosporine; FK,
tacrolimus; MTX, methotrexate; MMF, mycophenolate mofetil.
Data presented are n (%), unless otherwise indicated.
T. Schechter et al. / Biol Blood Marrow Transplant 21 (2015) 172e195 173monosomy 5 or 7, positive FLT3/ITD, or poor response to in-
duction chemotherapy [1]. Meshinchi et al. reported that the
event-free survival for children with FLT3/ITD was 7% and the
presence of FLT3/ITD was the single most important prog-
nostic factor for poor outcome [5]. Based on these ﬁndings,
children with FLT3/ITD are generally referred for allogeneic
HSCT in CR1 with the best available donor. Published reports
on the outcome of children with high-risk AML after alloge-
neic HSCT do not address the impact of FLT3/ITD on the post-
transplantation outcome [1,11,12]. We sought to examine the
outcome for all children with FLT3/ITDepositive AML who
underwent allogeneic HSCT.
PATIENTS AND METHODS
This retrospective study was approved by the participating institutions’
research ethics review boards. All pediatric patients diagnosed with FLT3/
ITDepositive AML who underwent myeloablative HSCT at 4 institutions (The
Hospital for Sick Children, Toronto, Canada; Monroe Carell Jr. Children’s Hos-
pital at Vanderbilt, Nashville, Tennessee; Fred Hutchinson Cancer Research
Center, Seattle, Washington; and RambamMedical Center, Haifa, Israel) from
March 2007 to June 2012 were included. FLT3/ITD molecular studies were
performedateach institution, according to localprotocols.All centersmaintain
a comprehensive and prospective database on all patients who undergo
transplantation. For patients identiﬁed with FLT3/ITD, the principal investi-
gator of the study at each center reviewed all availablemedical records, notes,
radiology reports, correspondence, and autopsy reports.
Stem cell sources were HLA-identical siblings or alternative donors.
Alternative donors included living related (other than siblings) or living
unrelated donors (deﬁned as 9/10 or 10/10, with high-resolution typing for
HLA-A, -B, -C, -DRB1, and -DQ) and cord blood stem cells (5/6 or 6/6 with
high-resolution typing for HLA-DRB1). Haplo-identical HSCT with ex vivo
T cell depletion was utilized when alternative donors were not identiﬁed.
The conditioning regimens used were based on institutional protocols.
Patients received busulfan-based or total body irradiation (TBI)e based
conditioning regimens. Graft-versus-host disease (GHVD) prophylaxis
included cyclosporine and methotrexate for patients receiving living donor
transplantations and cyclosporine with mycophenolate mofetil for cord
blood recipients. Patients with ex vivo T cell depletion did not receive GVHD
prophylaxis. The following information was identiﬁed from the blood and
marrow transplantation databases: age, gender, FLT3/ITD ratio at diagnosis
and before transplantation, stem cell source, conditioning regimen,
engraftment, and development of acute and/or chronic GVHD.
Statistical Analysis
Descriptive statistics, including median and range for continuous vari-
ables as well as percentages and frequencies for categorical variables, were
tabulated and presented. Overall survivalwas deﬁned as the time from HSCT
to death or last follow-up date. DFS was deﬁned as the time from HSCT to
relapse, death, or last follow-up date. Time to event curves were calculated
by the Kaplan-Meier method for groups of interest and were compared
using the log-rank test. Hazard ratios (HR) and 95% conﬁdence intervals (CI)
were estimated from Cox proportional hazard model.
RESULTS
Twenty-nine children with FLT3/ITDepositive AML who
underwent allogeneic HSCT between 2007 and 2012 were
included in this analysis. Characteristics of the patients and
transplantation procedures are shown in Table 1. All patients
had FLT3/ITDepositive tests. FLT3/ITD allelic ratios at the
time of diagnosis were available in 24 patients (range, .03 to
15.99). Fifteen patients (56%) had an FLT3/ITD allelic ratio
>.4. Twenty-ﬁve of 26 patients (96%) in CR1 had FLT3 testing
before transplantation and it was detected in 3 (12%). None of
the patients had associated high-risk monosomy karyotype.
Eighteen patients (62%) received a TBI (1320 cGy)-based
preparative regimen, either in combination with cyclophos-
phamide (n¼ 14) or with cyclophosphamide and ﬂudarabine
(n ¼ 4). A busulfan-containing regimen was used in 11 pa-
tients (8 patients had a combination of busulfan and cyclo-
phosphamide and 3 patients had a combination of busulfan
and ﬂudarabine). Eleven patients (38%) received stem cellsfromHLA-identical siblings and 18 patients (62%) received an
alternative donor stem cell source (mismatched related
donor [n¼ 2], unrelated donor [n¼ 7], or cord blood [n¼ 9]).
Single unit cord blood grafts were used in 6 patients
(matched for 6/6 [n ¼ 1], 5/6 [n ¼ 3], or 4/6 [n ¼ 2] HLA), and
double unit cord blood grafts were used in 3 patients. GVHD
prophylaxis was with calcineurin inhibitors and metho-
trexate in 19 patients (66%) (Table 1).
Primary graft failure occurred in 3 (10%) patients, all of
whom received single cord blood grafts. All 3 patients
received a second cord blood transplant that resulted in
sustained engraftment. The cumulative incidence of
neutrophil engraftment at day 42 was 89.6%. Sixteen (55%)
patients developed grade 2 to 4 acute GVHD and 11 (38%)
developed chronic GVHD (6 classiﬁed as severe and 5 as
mild). Relapse occurred in 11 (38%) patients at a median of
6.7 months (range, 2 to 33) after transplantation. The cu-
mulative incidence of relapse at 2 years was 34.7% (95% CI,
20.4% to 54.9%). The median follow-up of all patients is
29.4 months (range, 2 to 80 months). Six patients (5 in CR1
and 1 with relapsed disease at the time of transplantation)
died; all deaths were related to relapsed disease. At 2 years,
the probabilities of DFS and overall survival (OS) were 65.3%
(95% CI, 45.1% to 79.6%) and 82.2% (95% CI, 58.5% to 91.3%),
respectively (Figure 1).
In the univariable analysis, there was no difference be-
tween the DFS of patients who received transplants
from related donors versus the DFS of those with alternative
donors (HR, 2.64; 95%CI, .79 to8.76;P¼ .10). Therewas alsono
difference between DFS of patients with residual disease at
the time of transplantation versus those in CR (HR, .88; 95%CI,
.19 to 4.09; P ¼ .80). The use of TBI in the preparative
regimenwas associatedwith superior DFS andOS (HR, .29; 95
CI%, .08 to .99; P ¼ .04) and (HR, .07; 95% CI, .01 to .62;
P ¼ .002), respectively (Figure 2). Patients with higher FLT3/
ITD ratio at diagnosis had signiﬁcantly worse DFS (HR, 1.24;
95% CI, 1.02 to 1.49; P ¼ .03) and OS (HR, 1.25; 95% CI, .99 to
1.58; P ¼ .06).
Figure 1. Event-free (A) and overall survival (B).
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FLT3/ITD has been reported in up to 35% of adult AML
patients. Although FLT3/ITDepositive mutations are less
frequent in children comparedwith adults, theyarepresent in
13% to 16% of pediatric AML patients [3,5,7,13,14]. The pres-
ence of FLT3/ITD mutation is a powerful independent risk
factor for poor outcome in both adults and children [3,5,6].
The reported OS in these patients was 13%, compared with
50% for patients without FLT3/ITD mutation when treated
with chemotherapy alone. This poor outcome was attributed
to an increase in induction failure and a higher relapse rate.
Allogeneic HSCT has been used in adult patients with
FLT3/ITDepositive AML to decrease the risk of relapse and
improve DFS. The results have been mixed. Sengsayadeth
et al. reported inferior outcome after HSCT, with 2-year DFS
of 19% in FLT3/ITDepositive AML patients compared with
64% in patients with FLT3/ITDenegative AML. Time to relapse
was very short, with 100-day cumulative risk of 45%. Both
myeloablative and reduced-intensity conditioning regimens
were utilized in this study and patients who received mye-
loablative regimens had a delayed relapsed pattern [10].Gale et al. reported the outcome of 1135 adult AML patients
treated according to the United Kingdom Medical Research
Council AML protocols. In this study, 25% of the patients had
FLT3/ITD detected but the authors failed to show improved
outcomewith transplantation comparedwith chemotherapy
alone. The study showed higher relapse rate among patients
with FLT3/ITD treated with chemotherapy compared with
those without FLT3/ITD. Of note, the authors reported no
difference in the relapse rate after allogeneic HSCT when
comparing patients with or without FLT3/ITD. This observa-
tion suggests that allogeneic HSCT may negate the prog-
nostic signiﬁcance of FLT3/ITD [8]. In contrast, a large cohort
of 120 adult patients with FLT3/ITD from the European bone
marrow transplantation registry had a DFS of 58% at 2 years,
with a relapse rate of 30%. The authors concluded that allo-
geneic HSCT has a relevant role in the management of FLT3/
ITDepositive AML and recommended HSCT as the thera-
peutic option in CR1 [4]. Despite an improvement in outcome
for patients who received HSCT compared with chemo-
therapy alone, FLT3/ITD patients had a higher relapse rate
after transplantation compared with FLT3/ITDenegative pa-
tients (30%  5% versus 16%  5%, respectively [P ¼ .006]).
They also had lower leukemia-free survival. DeZern et al.
reported the outcome of 133 adult AML patients who were
treated at Johns Hopkins. The median OS from time of
diagnosis in FLT3/ITDeAML patients and their entire AML
cohort was 19.3 months versus 15.5 months, respectively
(P ¼ .56). The authors attributed the comparable outcome to
the increased use of HSCT in CR1 in FLT3/ITD patients
compared with other AML patients, with 60% of FLT3/ITD
patients undergoing allogeneic HSCT compared with 17% in
those without FLT3/ITD [13].
There is general agreement that allogeneic HSCT in CR1
is indicated in children with high-risk AML. High-risk
features include monosomy 7, monosomy 5, del(5q), high
FLT3/ITD allelic ratio, and poor response to induction
chemotherapy [15]. This recommendation is based pri-
marily on the observed poor response to chemotherapy,
not because the outcome has been shown to be signiﬁ-
cantly better with allogeneic HSCT. A recent report of 36
high-risk pediatric AML patients after HSCT in CR1
included only 6 patients with FLT3/ITDepositive AML. The
OS was 72% and DFS was 69% [1]. Although the outcome is
similar to our cohort, the authors did not report the
outcome of patients with FLT3/ITDepositive AML sepa-
rately. In our patients, the DFS and OS are signiﬁcantly
better than what has been reported with chemotherapy
alone in children with FLT3/ITD [3,5,7].
The importance of FLT3/ITD allelic ratio at diagnosis on DFS
after transplantation has been reported in adult patients. In a
recent study, an FLT3/ITD ratio .5 at time of diagnosis
adversely affected the outcome after transplantation. The risk
for relapse was 49%  10% in patients with in the low allelic
ratio group and 82%  7% in the high allelic ratio group
(P¼ .0075) [6]. In our study, patientswithhigher FLT3/ITD ratio
at the time of diagnosis had signiﬁcantly worse DFS and OS.
The use of TBI-based conditioning regimen, in our study,
was associated with an improved outcome. Prior studies
have shown no advantage of using a TBI-based preparative
regimen on the outcome of children with AML in second CR
[12]. These results should be interpreted with caution
because the use of TBI was based on local institutional pro-
tocols in each center. The importance of this ﬁnding in pa-
tients with FLT3/ITD can only be answered in a prospective
study comparing different types of conditioning regimens.
Figure 2. Event-free (A) and overall survival (B) for patients who received TBI-based versus busulfan-based preparative regimens.
T. Schechter et al. / Biol Blood Marrow Transplant 21 (2015) 172e195 175Although this study includes the largest number of pe-
diatric patients treated with HSCT for FLT3/ITD AML, the
conclusions are limited by the number of patients and by the
retrospective study design. For example, although these re-
sults support HSCT in CR1 regardless of donor stem cell
source, we cannot conclude with certainty that there is no
signiﬁcant difference in outcome because of the small
numbers of patients in each subset. Caution also must be
taken when comparing these results to those of patients
treated with chemotherapy only, as there is selection bias for
patients who were able to proceed to transplantation.
However, given these limitations, we can conclude that, for
patients who achieve remission and proceed to allogeneic
HSCT, the risk formortality from the procedure is lowand the
potential for leukemia-free survival is relatively high,
compared with expected results from chemotherapy alone.
Additional studies are required to evaluate the role of TBI in
this very high-risk patient population.
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